SLNO Fundamental Analysis - SOLENO THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to SLNO. SLNO was compared to 536 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.

In the past year SLNO has reported a negative cash flow from operations.

In the past 5 years SLNO always reported negative net income.

In the past 5 years SLNO always reported negative operating cash flow.

1.2 Ratios

SLNO has a Return On Assets of -54.49%. This is comparable to the rest of the industry: SLNO outperforms 46.83% of its industry peers.

SLNO's Return On Equity of -75.41% is in line compared to the rest of the industry. SLNO outperforms 54.66% of its industry peers.

		Industry Rank	Sector Rank
ROA	-54.49%
ROE	-75.41%
ROIC	N/A

ROA(3y)-55.18%

ROA(5y)-58.08%

ROE(3y)-109.68%

ROE(5y)-111.38%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLNO has more shares outstanding

SLNO has more shares outstanding than it did 5 years ago.

The debt/assets ratio for SLNO is higher compared to a year ago.

2.2 Solvency

SLNO has an Altman-Z score of 20.74. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 20.74, SLNO belongs to the top of the industry, outperforming 91.79% of the companies in the same industry.

SLNO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.

SLNO has a Debt to Equity ratio of 0.21. This is in the lower half of the industry: SLNO underperforms 68.47% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.21
Debt/FCF	N/A
Altman-Z	20.74

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

SLNO has a Current Ratio of 15.13. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 15.13, SLNO belongs to the best of the industry, outperforming 90.30% of the companies in the same industry.

SLNO has a Quick Ratio of 15.01. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 15.01, SLNO belongs to the best of the industry, outperforming 89.93% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	15.13
Quick Ratio	15.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.67%.

EPS 1Y (TTM)-69.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%84.21%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

SLNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.38% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y80.79%

EPS Next 2Y64.97%

EPS Next 3Y51.38%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.

A Price/Forward Earnings ratio of 21.74 indicates a rather expensive valuation of SLNO.

Based on the Price/Forward Earnings ratio, SLNO is valued cheaply inside the industry as 92.16% of the companies are valued more expensively.

SLNO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	21.74

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SLNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

SLNO's earnings are expected to grow with 51.38% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y64.97%

EPS Next 3Y51.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SLNO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (9/30/2025, 11:03:03 AM)

66.81

-1.35 (-1.98%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-06 2025-08-06/amc

Earnings (Next)11-04 2025-11-04/amc

Inst Owners108.63%

Inst Owner Change3.99%

Ins Owners1.42%

Ins Owner Change-0.29%

Market Cap3.55B

Analysts86.25

Price Target120.97 (81.07%)

Short Float %14%

Short Ratio3.95

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)40.18%

Min EPS beat(2)-0.42%

Max EPS beat(2)80.77%

EPS beat(4)1

Avg EPS beat(4)-28.52%

Min EPS beat(4)-186.49%

Max EPS beat(4)80.77%

EPS beat(8)2

Avg EPS beat(8)-30.55%

EPS beat(12)5

Avg EPS beat(12)-17.7%

EPS beat(16)8

Avg EPS beat(16)-9.16%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)10.15%

EPS NQ rev (1m)84.23%

EPS NQ rev (3m)104.85%

EPS NY rev (1m)22.49%

EPS NY rev (3m)75.13%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)229.02%

Revenue NY rev (1m)-0.19%

Revenue NY rev (3m)200.63%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	21.74
P/S	108.73
P/FCF	N/A
P/OCF	N/A
P/B	14.79
P/tB	15.16
EV/EBITDA	N/A

EPS(TTM)-4.14

EYN/A

EPS(NY)3.07

Fwd EY4.6%

FCF(TTM)-1.59

FCFYN/A

OCF(TTM)-1.59

OCFYN/A

SpS0.61

BVpS4.52

TBVpS4.41

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-54.49%
ROE	-75.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-55.18%

ROA(5y)-58.08%

ROE(3y)-109.68%

ROE(5y)-111.38%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0.21
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.53%
Cap/Sales	0.65%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	15.13
Quick Ratio	15.01
Altman-Z	20.74

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)3.83%

Cap/Depr(5y)2.6%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-69.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%84.21%

EPS Next Y80.79%

EPS Next 2Y64.97%

EPS Next 3Y51.38%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-165.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-283.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-282.33%

OCF growth 3YN/A

OCF growth 5YN/A

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens